Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Consolidated Statements of Operations and Comprehensive Loss
Revenues	$ 225,000	$ 0
Operating expenses:
Research and development	5,185,000	10,327,000
General and administrative	11,674,000	19,016,000
Total operating expenses	16,859,000	29,343,000
Operating loss	(16,634,000)	(29,343,000)
Other income (expense):
Interest expense	(172,000)	(83,000)
Interest income	363,000	213,000
Loss on sales of debt securities		(98,000)
Gain on sale of intellectual property	1,000,000
Total other income	1,191,000	32,000
Net loss from continuing operations	(15,443,000)	(29,311,000)
Loss from discontinued operations	(9,464,000)	(35,699,000)
Net loss	(24,907,000)	(65,010,000)
Comprehensive loss:
Consolidated net loss	(24,907,000)	(65,010,000)
Other comprehensive loss - unrealized loss on debt securities		180,000
Other comprehensive income - foreign currency adjustment		33,000
Comprehensive loss	$ (24,907,000)	$ (64,797,000)
Per share amount - continuing operations (Basic)	$ (4.03)	$ (47.88)
Per share amount - continuing operations (Diluted)	(4.03)	(47.88)
Per share amount - discontinued operations (Basic)	(2.47)	(58.31)
Per share amount - discontinued operations (Diluted)	(2.47)	(58.31)
Loss per common share attributable to iBio, Inc. stockholders - basic - total	(6.50)	(106.19)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total	$ (6.50)	$ (106.19)
Weighted-average common shares outstanding (Basic)	3,831	612
Weighted-average common shares outstanding (Diluted)	3,831	612